Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 9, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-016-0282-1
Keywords
Multiple myeloma; Novel agents; Immunomodulators; Proteasome inhibitors; Alkylating agents; AKT inhibitors; BTK inhibitors; CDK inhibitors; HDACIs; IL-6 inhibitors; Kinesin spindle protein inhibitors; Monoclonal antibodies; PI3K inhibitors
Categories
Ask authors/readers for more resources
Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An enhanced understanding of MM disease mechanisms has led to new more targeted treatments. There is now a plethora of treatments available for MM. In this review article, our aim is to discuss many of the novel agents that are being studied or have recently been approved for the treatment of MM. These agents include the following: immunomodulators (pomalidomide), proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors (afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat, rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies (daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available